Compugen (CGEN) Change in Accured Expenses (2009 - 2010)
Compugen (CGEN) posted quarterly Change in Accured Expenses of $1.1 million for Q4 2018, up 40.34% on a QoQ basis from $776000.0 in Q4 2010.
Powered by 
Analysis
Compugen (CGEN) Change in Accured Expenses (2009 - 2010) Analysis & Trends
Compugen has reported Change in Accured Expenses for 3 years, with the latest figure at $1.1 million in Q4 2018.
- Change in Accured Expenses for Q4 2018 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $1.1 million (changed N/A YoY), and the FY2025 annual result was $500000.0, up 118.59% from the prior year.
- Change in Accured Expenses improved to $1.1 million in Q4 2018, from $776000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $1.1 million in Q4 2018 and troughed at $1.1 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Compugen | 242.44 Mn | 156.82 Mn | -92,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2010 | 776,000.00 |
| Sep 30, 2010 | 61,000.00 |
| Dec 31, 2009 | 116,000.00 |
| Sep 30, 2009 | -224,000.00 |